<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7801109</article-id><article-id pub-id-type="pmid">33406941</article-id><article-id pub-id-type="doi">10.1080/14756366.2020.1868450</article-id><article-id pub-id-type="publisher-id">1868450</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Development of novel isatin&#x02013;nicotinohydrazide hybrids with potent activity against susceptible/resistant <italic>Mycobacterium tuberculosis</italic> and bronchitis causing&#x02013;bacteria</article-title><alt-title alt-title-type="left-running-head">Z. M. Elsayed et al.</alt-title><alt-title alt-title-type="right-running-head">Journal of Enzyme Inhibition and Medicinal Chemistry</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Elsayed</surname><given-names>Zainab M.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Eldehna</surname><given-names>Wagdy M.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Abdel-Aziz</surname><given-names>Marwa M.</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><name><surname>El Hassab</surname><given-names>Mahmoud A.</given-names></name><xref ref-type="aff" rid="AF0004">d</xref></contrib><contrib contrib-type="author"><name><surname>Elkaeed</surname><given-names>Eslam B.</given-names></name><xref ref-type="aff" rid="AF0005">e</xref><xref ref-type="aff" rid="AF0006">f</xref></contrib><contrib contrib-type="author"><name><surname>Al-Warhi</surname><given-names>Tarfah</given-names></name><xref ref-type="aff" rid="AF0007">g</xref></contrib><contrib contrib-type="author"><name><surname>Abdel-Aziz</surname><given-names>Hatem A.</given-names></name><xref ref-type="aff" rid="AF0008">h</xref></contrib><contrib contrib-type="author"><name><surname>Abou-Seri</surname><given-names>Sahar M.</given-names></name><xref ref-type="aff" rid="AF0009">i</xref></contrib><contrib contrib-type="author"><name><surname>Mohammed</surname><given-names>Eman R.</given-names></name><xref ref-type="aff" rid="AF0009">i</xref></contrib><aff id="AF0001"><label>a</label><institution>Faculty of Pharmacy, Scientific Research and Innovation Support Unit, Kafrelsheikh University</institution>, <city>Kafrelsheikh</city>, <country>Egypt</country></aff><aff id="AF0002"><label>b</label><institution>Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Kafrelsheikh University</institution>, <city>Kafrelsheikh</city>, <country>Egypt</country></aff><aff id="AF0003"><label>c</label><institution>The Regional Center for Mycology &#x00026; Biotechnology, Al-Azhar University</institution>, <city>Cairo</city>, <country>Egypt</country></aff><aff id="AF0004"><label>d</label><institution>Department of Pharmaceutical Chemistry, School of Pharmacy, Badr University in Cairo</institution>, <city>Badr City</city>, <country>Egypt</country></aff><aff id="AF0005"><label>e</label><institution>Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University</institution>, <city>Ad Diriyah</city>, <country>Saudi Arabia</country></aff><aff id="AF0006"><label>f</label><institution>Faculty of Pharmacy (Boys), Department of Pharmaceutical Organic Chemistry, Al-Azhar University</institution>, <city>Cairo</city>, <country>Egypt</country></aff><aff id="AF0007"><label>g</label><institution>Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University</institution>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff><aff id="AF0008"><label>h</label><institution>Department of Applied Organic Chemistry, National Research Center</institution>, <city>Giza</city>, <country>Egypt</country></aff><aff id="AF0009"><label>i</label><institution>Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Cairo University</institution>, <city>Cairo</city>, <country>Egypt</country></aff></contrib-group><author-notes><fn id="AUFN1"><p content-type="appended text">Supplemental data for this article can be accessed <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1868450"><underline>here</underline></ext-link>.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Wagdy M. Eldehna <email>wagdy2000@gmail.com</email><institution>Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Kafrelsheikh University</institution>, <addr-line>P.O. Box 33516</addr-line>, <city>Kafrelsheikh</city>, <country>Egypt</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>7</day><month>1</month><year>2021</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>36</volume><issue>1</issue><fpage seq="37">384</fpage><lpage>393</lpage><permissions><copyright-statement>&#x000a9; 2021 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_36_1868450.pdf"/><abstract><title>Abstract</title><p>Joining the global fight against Tuberculosis, the world's most deadly infectious disease, herein we present the design and synthesis of novel isatin-nicotinohydrazide hybrids (<bold>5a&#x02013;m</bold> and <bold>9a&#x02013;c</bold>) as promising anti-tubercular and antibacterial agents. The anti-tubercular activity of the target hybrids was evaluated against drug-susceptible M. tuberculosis strain (ATCC 27294) where hybrids <bold>5d</bold>, <bold>5g</bold> and <bold>5h</bold> were found to be as potent as INH with MIC = 0.24 &#x000b5;g/mL, also the activity was evaluated against Isoniazid/Streptomycin resistant M. tuberculosis (ATCC 35823) where compounds <bold>5g</bold> and <bold>5h</bold> showed excellent activity (MIC = 3.9 &#x000b5;g/mL). Moreover, the target hybrids were examined against six bronchitis causing-bacteria. Most derivatives exhibited excellent antibacterial activity. K. pneumonia emerged as the most sensitive strain with MIC range: 0.49&#x02013;7.81 &#x000b5;g/mL. Furthermore, a molecular docking study has proposed DprE1 as a probable enzymatic target for herein reported isatin-nicotinohydrazide hybrids, and explored the binding interactions within the vicinity of DprE1 active site.</p></abstract><abstract abstract-type="graphical"><title>GRAPHICAL ABSTRACT</title><fig id="UF0001" orientation="portrait" position="anchor"><graphic content-type="color" xlink:href="IENZ_A_1868450_UF0001_C"/></fig></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Anti-tubercular activity</kwd><kwd>DprE1 inhibitors</kwd><kwd>resistant TB</kwd><kwd>nicotinohydrazide</kwd><kwd>isatin derivatives</kwd></kwd-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="9"/><word-count count="6061"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Tuberculosis (TB) is considered to be the world&#x02019;s top infectious killer<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. It is a complicated devastating disease that accounts for the death of 1.5 million individuals in 2018 as declared by WHO<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. About 23% of the world&#x02019;s population is expected to be latent TB carriers with a high risk to develop the disease<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. The first-line drugs such as Isoniazid, Rifampicin, Ethambutol, and Streptomycin have shown significant activity against <italic>Mycobacterium tuberculosis</italic> however, the emergency of drug-resistant TB (DR-TB), especially multi-drug resistant TB (MDR-TB) is still a serious trouble<xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref>. The emerged drug resistance can be considered as a global health crisis, where only one out of three accessing proper remedy among the patients falling ill in 2018<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>.</p><p>Along with the emerged drug resistance, the development of secondary bacterial infection is considered to be a critical problem<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref>. Different bacterial strains have been isolated from sputum samples including: <italic>Haemophilus influenzae</italic>, <italic>Klebsiella pneumoniae</italic>, <italic>Streptococcus pneumoniae</italic>, and <italic>Moraxella catarrhalis</italic><xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>. The tubercular and the bacterial co-infection can lead to inadequate treatment causing serious complications such as pneumoniae, bronchial anthracofibrosis, and chronic airflow obstruction<xref rid="CIT0005" ref-type="bibr"><sup>5&#x02013;8</sup></xref>. Unfortunately, many virulent bacterial strains have developed bacterial resistance against most of the currently used antibiotics. The death rate due to bronchitis has been increased up to an alarming level recording about 0.7 million cases of death every year. Thus, there is a crucial need to design and synthesise new candidates that may help in the battle of the developed bacterial resistance towards the currently available anti-tubercular and antibacterial drugs.</p><p>Isatin is a promising endogenous biologically active scaffold. It could be chemically modified to produce various heterocyclic compounds with different biological activities<xref rid="CIT0009" ref-type="bibr"><sup>9&#x02013;14</sup></xref>. Isatin based derivatives have revealed promising antibacterial<xref rid="CIT0015" ref-type="bibr"><sup>15&#x02013;17</sup></xref> and anti-TB effects<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>. Moreover, the nicotinohydrazide moiety has a large contribution to the field of medicinal chemistry. It has been incorporated in several active antimicrobial<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref> and anti-tubercular agents<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>. In fact, the presence of a hydrazide group can be considered as a significant key for an optimum anti-tubercular activity<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>. Recently, several research teams adopted molecular hybridisation techniques between isatin and different moieties for the design of new anti-mycobacterial agents<xref rid="CIT0023" ref-type="bibr"><sup>23&#x02013;26</sup></xref>, such as isatin-INH hybrids <bold>I</bold> (<xref ref-type="fig" rid="F0001">Figure 1</xref>)<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref> and isatin-nalidixic acid hybrids <bold>II</bold> (<xref ref-type="fig" rid="F0001">Figure 1</xref>)<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref>. Later, our research team has identified the <italic>N</italic>-substituted isatin-thiazolidinone hybrid <bold>III</bold> (<xref ref-type="fig" rid="F0001">Figure 1</xref>) as a promising antitubercular agent that produced an effective killing of <italic>M. aurum</italic> in infected macrophage model with broad-spectrum antimicrobial effect against sensitive and resistant bacterial strains<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref>. SAR study revealed that <italic>N</italic>-benzylation or <italic>N</italic>-methylation of the 2-oxindole ring enhanced the activity by 2-4 folds as compared to the <italic>N</italic>-unsubstituted analogues.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Structures of some reported isatin-based anti-mycobacterial agents (<bold>I&#x02013;III</bold>).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1868450_F0001_C"/></fig><p>In view of the findings stated above and in a continuation of our previous work for the discovery of potential anti-tubercular and anti-microbial agents<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref>, we decided to extend our research through conjugating different <italic>N</italic>-substituted isatin moieties with a nicotinohydrazide moiety to furnish target hybrids <bold>5a-I</bold> (<xref ref-type="fig" rid="F0002">Figure 2</xref>). In order to explore the impact of C-5 substitution, as well as to ensure different lipophilic environments that may be suitable for the mycobacterial activity, both 5-Cl and 5-Br substituents were grafted at isatin scaffold. As it was suggested that <italic>N</italic>-substitution of isatin scaffold could enhance the mycobacterial activity<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref>, <italic>N</italic>-alkylation, or <italic>N</italic>-benzylation of the herein reported hybrids was performed (<xref ref-type="fig" rid="F0002">Figure 2</xref>). Thereafter, the impact of C-2 and C-6 substitution of the nicotinohydrazide moiety the anti-tubercular and antibacterial activities were investigated through developing the two sets <bold>5j&#x02013;m</bold> and <bold>9a&#x02013;c</bold> (<xref ref-type="fig" rid="F0002">Figure 2</xref>). Finally, an isatin-3-pyridylamine hybrid <bold>14</bold> was synthesised to carry out further elaboration of the target scaffold (<xref ref-type="fig" rid="F0002">Figure 2</xref>).</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Design of the target hybrids <bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold>, and <bold>14</bold>.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1868450_F0002_C"/></fig><p>Herein seventeen new 2-oxindolin-3-ylidene-nicotinohydrazide derivatives (<bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold>, and <bold>14</bold>) were designed, synthesised, and evaluated for their anti-tubercular activity against drug-susceptible <italic>M. tuberculosis</italic> strain (ATCC 27294) and Isoniazid/Streptomycin resistant <italic>M. tuberculosis</italic> (ATCC 35823), together with the antibacterial effect against bronchitis causing-bacteria in an attempt to produce new candidates having potential activities with minimal bacterial resistance that may reduce the complications associated with the secondary bacterial infection.</p><p>Finally, molecular docking studies have been performed for the most active compounds into the active sites of two enzymes: flavoenzyme Decaprenylphosphoryl-<italic>&#x003b2;</italic>-D-Ribose 2&#x02032;-Epimerase (DprE1) and enoyl-acyl carrier protein reductase (InhA) being critical enzymes in the metabolism and synthesis of <italic>M. tuberculosis</italic> cell wall<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref> to explore the possible mechanism of action of the new hybrids.</p></sec><sec sec-type="results" id="S0002" disp-level="1"><label>2.</label><title>Results and discussion</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Chemistry</title><p>The synthetic strategies adopted for the preparation of final compounds (<bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold> and <bold>14</bold>) were illustrated in <xref ref-type="scheme" rid="SCH0001 SCH0002 SCH0003">Schemes 1&#x02013;3</xref>. In the first scheme, different isatin derivatives <bold>3a&#x02013;c</bold> were alkylated with the appropriate alkyl halide in anhydrous DMF in the presence of K<sub>2</sub>CO<sub>3</sub> as an acid binder to furnish the <italic>N</italic>-substituted indoline-2,3-diones <bold>4a&#x02013;i</bold>. On the other hand, methyl nicotinate <bold>1a</bold> and methyl 6-methoxynicotinate <bold>1b</bold> was refluxed with hydrazine hydrate in methanol to produce the key intermediate nicotinohydrazides <bold>2a&#x02013;b</bold> which subsequently reacted with <italic>N</italic>-substituted indoline-2,3-dione derivatives <bold>4a&#x02013;i</bold> in absolute ethanol containing a catalytic amount of glacial acetic acid to get the final compounds <bold>5a&#x02013;m</bold> (<xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>).</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthesis of target isatin hybrids <bold>5a&#x02013;m</bold>; (<bold>i</bold>) NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O/methanol/reflux 4&#x02009;h, (<bold>ii</bold>) R<sub>1</sub>-Br/DMF/KI (Cat.)/K<sub>2</sub>CO<sub>3</sub>/reflux 3&#x02009;h, (<bold>iii</bold>) Ethanol absolute/drops glacial acetic acid (Cat.)/reflux 6&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1868450_SCH0001_B"/></fig><fig id="SCH0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Synthesis of target isatin hybrids <bold>9a&#x02013;c</bold>; (<bold>i</bold>) ethyl acetoacetate/NH<sub>4</sub>OAc/glacial acetic acid/reflux 6&#x02009;h, (<bold>ii</bold>) NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O/methanol/reflux 6&#x02009;h, (<bold>iii</bold>) Ethanol absolute/drops glacial acetic acid (Cat.)/reflux 6&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1868450_SCH0002_B"/></fig><fig id="SCH0003" orientation="portrait" position="float"><label>Scheme 3.</label><caption><p>Synthesis of target compound <bold>14</bold>; (<bold>i</bold>) NaOH/MeOH/reflux 6&#x02009;h, (<bold>ii</bold>) SOCl<sub>2</sub>/reflux 4&#x02009;h, (<bold>iii</bold>) NaN<sub>3</sub>/acetone/stirring at R.T. 4&#x02009;h, (<bold>iv</bold>) Dry toluene/reflux 1&#x02009;h, (<bold>v</bold>) Dry toluene/reflux 5&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1868450_SCH0003_B"/></fig><p>In the second scheme, 3-(dimethylamino)-1-phenylprop-2-en-1-one <bold>6</bold> was heated under reflux with ethyl acetoacetate and NH<sub>4</sub>OAc in glacial acetic acid to produce ethyl 2-methyl-6-phenylnicotinate <bold>7</bold> in which, the ester moiety was subjected to hydrazinolysis to produce the key intermediate 2-methyl-6-phenylnicotinohydrazide <bold>8</bold> which reacted with different <italic>N</italic>-substituted indoline-2,3-diones <bold>4a&#x02013;c</bold> to get target compounds <bold>9a&#x02013;c</bold>.</p><p>In the last scheme, methyl 6-methoxynicotinate <bold>1b</bold> was refluxed with NaOH in MeOH to get the free 6-methoxynicotinic acid <bold>10</bold>, which then undergone to chlorination <italic>via</italic> SOCl<sub>2</sub> to furnish 6-methoxynicotinoyl chloride <bold>11</bold> where the chloride was subsequently substituted with an azide functionality to produce 6-methoxynicotinoyl azide <bold>12</bold>. The azid derivative <bold>12</bold> was subjected to Curtius Rearrangement to get 5-isocyanato-2-methoxypyridine <bold>13</bold>, that refluxed with 5-bromoindoline-2,3-dione <bold>3c</bold> in dry toluene to furnish the final compound <bold>14</bold>.</p><p><sup>1</sup>H NMR spectra of the final compounds <bold>5a&#x02013;m</bold> and <bold>9a&#x02013;c</bold> were confirmed with the presence of a D<sub>2</sub>O exchangeable singlet signal attributable to the proton of the hydrazide linker at <italic>&#x003b4;</italic> (13.31&#x02013;13.86) ppm. Moreover, <sup>1</sup>H NMR spectra for compounds <bold>9a&#x02013;c</bold> confirmed the presence of singlet signal in the aliphatic region for the CH<sub>3</sub> group around <italic>&#x003b4;</italic> 2.71&#x02009;ppm, in addition to the extra aromatic protons for the 6-phenyl ring at a range of <italic>&#x003b4;</italic> 7.44&#x02013;7.57&#x02009;ppm, whereas, spectra for compounds <bold>5j&#x02013;m</bold> and <bold>14</bold> confirmed the appearance of singlet signal for OCH<sub>3</sub> groups at <italic>&#x003b4;</italic> (3.82&#x02013;3.97) ppm.</p><p>In addition, the propyl moiety in compounds (<bold>5a</bold>, <bold>e</bold>, <bold>g</bold>, <bold>j</bold>, and <bold>9a</bold>) was confirmed with the appearance of two triplet signals for (&#x02013;CH<sub>2</sub>C<underline>H<sub>3</sub></underline>) and (<italic>N</italic>-CH<sub>2</sub>) at <italic>&#x003b4;</italic> (0.89-0.91) and (3.70&#x02013;3.75) ppm, respectively. Also, <sup>1</sup>H NMR spectra for compounds (<bold>5b</bold>, <bold>f</bold>, <bold>h</bold>, <bold>k</bold>, and, <bold>9b</bold>) displayed two doublet signals for (&#x02013;CH(C<underline>H<sub>3</sub></underline>)<sub>2</sub>) and (<italic>N</italic>-CH<sub>2</sub>) in the isobutyl moiety at <italic>&#x003b4;</italic> (0.90-0.93) and (3.56-3.74) ppm, respectively, whereas, the ethyl acetate group of compounds (<bold>5c</bold>, <bold>i</bold>, <bold>l</bold>, and <bold>9c</bold>) was represented by a triplet signal for (CO-CH<sub>2</sub>C<underline>H<sub>3</sub></underline>), quartette signal for (CO&#x02013;C<underline>H<sub>2</sub></underline>CH<sub>3</sub>) as well as singlet signal for (<italic>N</italic>-CH<sub>2</sub>) at <italic>&#x003b4;</italic> (1.20&#x02013;1.22), (4.16&#x02013;4.17) and (4.72&#x02013;7.74) ppm, respectively. Furthermore, the <italic>N</italic>-benzyl substituted counterparts (<bold>5d</bold> and 5<bold>m</bold>) showed singlet signals around <italic>&#x003b4;</italic> 5.02&#x02009;ppm attributed to the benzylic (&#x02013;C<underline>H<sub>2</sub></underline>&#x02013;C<sub>6</sub>H<sub>5</sub>) protons.</p><p>On the other hand, <sup>13&#x02009;</sup>C NMR spectra for hybrids <bold>5a&#x02013;m</bold> and <bold>9a&#x02013;c</bold> showed two signals resonating in the range <italic>&#x003b4;</italic> (161.20&#x02013;161.84) and (162.90&#x02013;166.52) ppm attributable for the carbonyl carbons of the nicotinic hydrazide and indoline-2-one moieties, respectively. Moreover, compounds <bold>5c</bold>, <bold>l</bold>, and <bold>9c</bold> showed an extra signal for C&#x02009;=&#x02009;O group for the ester moiety at <italic>&#x003b4;</italic> 167.86&#x02009;ppm, whereas, compound <bold>14</bold> displayed the C&#x02009;=&#x02009;O signal for urea linker at <italic>&#x003b4;</italic> 153.69&#x02009;ppm, and two signals for indoline-2,3-dione moiety at <italic>&#x003b4;</italic> 159.57 and 183.65&#x02009;ppm. Additionally, <sup>13&#x02009;</sup>C NMR spectra for compounds <bold>9a&#x02013;c</bold> showed a signal corresponding to CH<sub>3</sub> carbon at <italic>&#x003b4;</italic> 23.88&#x02013;27.24&#x02009;ppm, while, spectra for compounds <bold>5j&#x02013;m</bold> and <bold>14</bold> displayed a signal corresponding to OCH<sub>3</sub> carbon at <italic>&#x003b4;</italic> (53.53&#x02013;54.44) ppm.</p><p>Furthermore, the carbons of the <italic>N</italic>-propyl group in compounds (<bold>5a</bold>, <bold>e</bold>, <bold>g</bold>, <bold>k</bold>, and <bold>9a</bold>) appeared as three signals resonating at <italic>&#x003b4;</italic> (11.60&#x02013;11.65&#x02009;ppm), (20.81&#x02013;20.87&#x02009;ppm), and (41.28&#x02013;41.48&#x02009;ppm) for &#x02013;CH<sub>2</sub><underline>C</underline>H<sub>3</sub>, <italic>N</italic>-CH<sub>2</sub><underline>C</underline>H<sub>2</sub>, and <italic>N</italic>-CH<sub>2</sub>, respectively, and the carbons of the <italic>N</italic>-isobutyl group in compounds (<bold>5f</bold>, <bold>l</bold> and <bold>9b</bold>) appeared as three signals at a range of <italic>&#x003b4;</italic> (20.36&#x02013;20.45&#x02009;ppm), (27.22&#x02013;23.88&#x02009;ppm) and (47.10&#x02013;56.51&#x02009;ppm) due to &#x02013;CH(<underline>C</underline>H<sub>3</sub>)<sub>2</sub>&#x02013;, &#x02013;<underline>C</underline>H(CH<sub>3</sub>)<sub>2</sub>&#x02013; and &#x02013;<italic>N</italic>-CH<sub>2</sub>&#x02013;, respectively. Finally, a signal attributable to the benzylic (&#x02013;CH<sub>2</sub>&#x02013;) carbon in the <italic>N</italic>-benzyl derivatives (<bold>5d</bold> and 5<bold>m</bold>) appeared around <italic>&#x003b4;</italic> 43.10&#x02009;ppm.</p></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Biological evaluation</title><sec id="S0002-S2002-S3001" disp-level="3"><label>2.2.1.</label><title>Anti-tubercular activity</title><p>All of the newly synthesised hybrids were evaluated for their anti-tubercular action towards <italic>M. tuberculosis</italic> (ATCC 27294) using the Microplate Alamar Blue Assay (MABA)<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>. INH was used as the reference drug. The obtained results for the anti-mycobacterial activity were summarised in (<xref rid="t0001" ref-type="table">Table 1</xref>) and expressed as a minimum inhibitory concentration (MIC).</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>MIC (&#x000b5;g/mL) for hybrids (<bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold>, and <bold>14</bold>) against <italic>M. tuberculosis</italic> (ATCC 27294) and Isoniazid/Streptomycin resistant <italic>M. tuberculosis</italic> (ATCC 35823), and LogP measurements for hybrids (<bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold>, and <bold>14</bold>).<inline-graphic xlink:href="IENZ_A_1868450_ILG0001_B.jpg" content-type="black-white"/></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Compound</th><th align="center">X or R<sub>2</sub></th><th align="center">R</th><th align="center">R<sub>1</sub></th><th align="center"><italic toggle="yes">M. tuberculosis</italic> (ATCC 27294)</th><th align="center"><italic toggle="yes">M. tuberculosis</italic> (ATCC 35823)</th><th align="center">LogP</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>5a</bold></td><td align="left">H</td><td align="left">&#x02013;CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td><td align="left">&#x000a0;</td><td align="char" char=".">3.9</td><td align="char" char=".">125</td><td align="char" char=".">1.65</td></tr><tr><td align="left"><bold>5b</bold></td><td align="left">H</td><td align="left">&#x02013;CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td align="left">&#x000a0;</td><td align="char" char=".">1.95</td><td align="char" char=".">62.5</td><td align="char" char=".">2.04</td></tr><tr><td align="left"><bold>5c</bold></td><td align="left">H</td><td align="left">&#x02013;CH<sub>2</sub>COOCH<sub>2</sub>CH<sub>3</sub></td><td align="left">&#x000a0;</td><td align="char" char=".">7.81</td><td align="char" char=".">NA</td><td align="char" char=".">1.46</td></tr><tr><td align="left"><bold>5d</bold></td><td align="left">H</td><td align="left">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub></td><td align="left">&#x000a0;</td><td align="char" char="."><bold>0.24</bold></td><td align="char" char="."><bold>15.63</bold></td><td align="char" char=".">2.55</td></tr><tr><td align="left"><bold>5e</bold></td><td align="left">Cl</td><td align="left">&#x02013;CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td><td align="left">&#x000a0;</td><td align="char" char=".">3.9</td><td align="char" char=".">NA</td><td align="char" char=".">2.2</td></tr><tr><td align="left"><bold>5f</bold></td><td align="left">Cl</td><td align="left">&#x02013;CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td align="left">&#x000a0;</td><td align="char" char=".">0.48</td><td align="char" char="."><bold>15.63</bold></td><td align="char" char=".">2.6</td></tr><tr><td align="left"><bold>5g</bold></td><td align="left">Br</td><td align="left">&#x02013;CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td><td align="left">&#x000a0;</td><td align="char" char="."><bold>0.24</bold></td><td align="char" char="."><bold>3.9</bold></td><td align="char" char=".">2.47</td></tr><tr><td align="left"><bold>5h</bold></td><td align="left">Br</td><td align="left">&#x02013;CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td align="left">&#x000a0;</td><td align="char" char="."><bold>0.24</bold></td><td align="char" char="."><bold>3.9</bold></td><td align="char" char=".">2.87</td></tr><tr><td align="left"><bold>5i</bold></td><td align="left">Br</td><td align="left">&#x02013;CH<sub>2</sub>COOCH<sub>2</sub>CH<sub>3</sub></td><td align="left">&#x000a0;</td><td align="char" char=".">7.81</td><td align="char" char=".">NA</td><td align="char" char=".">2.29</td></tr><tr><td align="left"><bold>5j</bold></td><td align="left">H</td><td align="left">&#x02013;CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td><td align="left">OCH<sub>3</sub></td><td align="char" char=".">0.98</td><td align="char" char="."><bold>15.63</bold></td><td align="char" char=".">2.24</td></tr><tr><td align="left"><bold>5k</bold></td><td align="left">H</td><td align="left">&#x02013;CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td align="left">OCH<sub>3</sub></td><td align="char" char=".">0.98</td><td align="char" char=".">62.5</td><td align="char" char=".">2.63</td></tr><tr><td align="left"><bold>5l</bold></td><td align="left">H</td><td align="left">&#x02013;CH<sub>2</sub>COOCH<sub>2</sub>CH<sub>3</sub></td><td align="left">OCH<sub>3</sub></td><td align="char" char=".">3.9</td><td align="char" char=".">125</td><td align="char" char=".">2.05</td></tr><tr><td align="left"><bold>5m</bold></td><td align="left">H</td><td align="left">&#x02013;CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub></td><td align="left">OCH<sub>3</sub></td><td align="char" char=".">7.81</td><td align="char" char=".">NA</td><td align="char" char=".">3.14</td></tr><tr><td align="left"><bold>9a</bold></td><td align="left">CH<sub>3</sub></td><td align="left">&#x02013;CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td><td align="left">C<sub>6</sub>H<sub>5</sub></td><td align="char" char=".">31.25</td><td align="char" char=".">NA</td><td align="char" char=".">4.45</td></tr><tr><td align="left"><bold>9b</bold></td><td align="left">CH<sub>3</sub></td><td align="left">&#x02013;CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td align="left">C<sub>6</sub>H<sub>5</sub></td><td align="char" char=".">15.63</td><td align="char" char=".">NA</td><td align="char" char=".">4.85</td></tr><tr><td align="left"><bold>9c</bold></td><td align="left">CH<sub>3</sub></td><td align="left">&#x02013;CH<sub>2</sub>COOCH<sub>2</sub>CH<sub>3</sub></td><td align="left">C<sub>6</sub>H<sub>5</sub></td><td align="char" char=".">15.63</td><td align="char" char=".">NA</td><td align="char" char=".">4.26</td></tr><tr><td align="left"><bold>14</bold></td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="char" char=".">3.9</td><td align="char" char=".">62.5</td><td align="char" char=".">1.94</td></tr><tr><td align="left"><bold>INH</bold></td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="char" char=".">0.24</td><td align="char" char=".">&#x0003e;125</td><td align="char" char=".">&#x000a0;</td></tr><tr><td align="left"><bold>Streptomycin</bold></td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="char" char=".">&#x000a0;</td><td align="char" char=".">&#x0003e;125</td><td align="char" char=".">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>NA: not determined, MIC &#x0003e;125&#x02009;&#x000b5;g/mL.</p></fn><fn id="TF100"><p>Bold values represent the best activity.</p></fn></table-wrap-foot></table-wrap><p>The results revealed that most tested compounds exerted potent to moderate anti-tubercular action with MIC range = 0.24-7.81&#x02009;&#x000b5;g/mL. Compounds <bold>5d</bold>, <bold>5g</bold>, and <bold>5h</bold> were found to be as potent as INH with MIC = 0.24&#x02009;&#x000b5;g/mL. Compounds <bold>5f</bold>, <bold>5j</bold>, and <bold>5k</bold> revealed potent activity with MIC range = 0.48&#x02013;0.98&#x02009;&#x000b5;g/mL, whereas derivatives <bold>5a&#x02013;5c</bold>, <bold>5e</bold>, <bold>5i</bold>, <bold>5l</bold>, <bold>5m</bold>, and <bold>14</bold> exhibited a moderate activity with MIC range = 1.95&#x02013;7.81&#x02009;&#x000b5;g/mL.</p><p>Concerning the structure&#x02013;activity relationship, it was observed that the anti-tubercular activity of compounds <bold>5a&#x02013;5i</bold> was affected by two main factors; <italic>N</italic>-substitution and incorporation of halogen at position 5 of the oxindole ring. Regarding <italic>N</italic>-substitution it was shown that, compounds bearing isobutyl group: <bold>5b</bold>, <bold>5f</bold>, and <bold>5h</bold> exhibited remarkable activity with MIC values = 1.95, 0.48, and 0.24&#x02009;&#x000b5;g/mL, respectively. Similarly, compound <bold>5d</bold> with <italic>N</italic>-benzyl moiety revealed a potent activity with MIC = 0.24&#x02009;&#x000b5;g/mL. In contrast, compounds <bold>5c</bold> and <bold>5i</bold> carrying the <italic>N</italic>-ethylcarboxylate group were found to be the least active derivatives (MIC = 7.81&#x02009;&#x000b5;g/mL). Moreover, the contribution of substitution at position 5 of oxindole ring on the activity was quite important. Incorporating 5-Br group in compounds <bold>5g</bold> and <bold>5h</bold> (MIC = 0.24&#x02009;&#x000b5;g/mL) showed better activity than 5-Cl substituted compounds <bold>5e</bold> and <bold>5f</bold> (MIC = 0.48 and 3.9&#x02009;&#x000b5;g/mL, respectively) and the unsubstituted congeners <bold>5a&#x02013;5c</bold> (MIC range = 3.9&#x02013;7.81&#x02009;&#x000b5;g/mL).</p><p>Then we turned our attention to study the impact of substitution at position 6 on the nicotinohydrazide moiety of the new hybrids. Comparing the anti-tubercular activity of 6-methoxy nicotinohydrazide derivatives <bold>5j&#x02013;5m</bold> against the unsubstituted counterparts <bold>5a&#x02013;5d</bold>, it was found that the introduction of 6-methoxy group in compounds <bold>5j&#x02013;5l</bold> (MIC = 0.98-3.9&#x02009;&#x000b5;g/mL) enhanced the anti-tubercular activity by 2-4 fold compared to unsubstituted analogues <bold>5a&#x02013;5c</bold> (MIC range: 1.95&#x02013;7.81&#x02009;&#x000b5;g/mL) except for the benzyl derivatives <bold>5d</bold> and <bold>5m</bold>. Conversely, the introduction of 6-phenyl moiety to the nicotinohydrazide moiety as in compounds <bold>9a&#x02013;c</bold> (MIC = 15.63&#x02013;31.25&#x02009;&#x000b5;g/mL) led to a reduced anti-tubercular activity that may be due to steric factors.</p><p>In conclusion, increasing the lipophilicity of the isatin scaffold via C-5 substitution with halogens (Br&#x02009;&#x0003e;&#x02009;Cl) was more advantageous for activity. Also, the anti-mycobacterial action of the target hybrids was decreased in the following order; 6-methoxy nicotinohydrazide&#x02009;&#x0003e;&#x02009;unsubstituted nicotinohydrazide &#x0003e; 2-methyl-6-phenyl nicotinohydrazide (<xref ref-type="fig" rid="F0003">Figure 3</xref>).</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Summary for the structure activity relationships for anti-mycobacterial activity of the target hybrids.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1868450_F0003_C"/></fig></sec><sec id="S0002-S2002-S3002" disp-level="3"><label>2.2.2.</label><title>Anti-tubercular activity towards Isoniazid and Streptomycin resistant M. tuberculosis (ATCC 35823)</title><p>The anti-tubercular activity against Isoniazid and Streptomycin resistant <italic>M. tuberculosis</italic> (ATCC 35823) was evaluated using MABA<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>. Investigating the results of the target compounds <bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold>, and <bold>14</bold> (<xref rid="t0001" ref-type="table">Table 1</xref>), it was found that many of the tested derivatives exhibited potent to moderate activity with MIC range = 3.9-62.5&#x02009;&#x000b5;g/mL. Compounds <bold>5g</bold> and <bold>5h</bold> with the best anti-tubercular effect against <italic>M. tuberculosis</italic> (ATCC 27294), showed excellent activity (MIC = 3.9&#x02009;&#x000b5;g/mL) resistant <italic>M. tuberculosis</italic> strain (ATCC 35823), with more than 32 fold increase in the activity compared to INH and Streptomycin (MIC &#x0003e; 125&#x02009;&#x000b5;g/mL). Moreover, compounds <bold>5d</bold>, <bold>5f</bold> and <bold>5j</bold> elicited a good activity with MIC = 15.63&#x02009;&#x000b5;g/mL, whereas derivatives <bold>5b</bold>, <bold>5k</bold>, and <bold>14</bold> produced a moderate activity with MIC = 62.5&#x02009;&#x000b5;g/mL. Finally, compounds <bold>5a</bold> and <bold>5l</bold> were found to be least active showing MIC value = 125&#x02009;&#x000b5;g/mL, while the 6-phenyl pyridine derivatives <bold>9a&#x02013;c</bold> were inactive with MIC &#x0003e;125&#x02009;&#x000b5;g/mL.</p></sec><sec id="S0002-S2002-S3003" disp-level="3"><label>2.2.3.</label><title>Antibacterial activity against bronchitis causing-bacteria</title><p>The antibacterial activity for the synthesised compounds <bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold>, and <bold>14</bold> was evaluated against bronchitis causing-bacteria; Gram-negative <italic>Mycoplasma pneumoniae</italic> (ATCC 15531), <italic>K. pneumoniae</italic> (ATCC 43816), <italic>H. influenzae</italic> (ATCC 10211), <italic>M. catarrhalis</italic> (ATCC 25238), <italic>B. pertussis</italic> (ATCC 9340) and Gram-positive <italic>S. pneumoniae</italic> (ATCC 1659) using XTT Susceptibility Assay (<xref rid="t0002" ref-type="table">Table 2</xref>)<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>. The results showed that, most of the evaluated compounds produced a significant antibacterial activity in comparison to the reference drug Azithromycin against the tested bacterial strains. The most sensitive strain towards the new hybrids was <italic>K. pneumoniae</italic> (ATCC 43816) with MIC range = 0.49&#x02013;7.81&#x02009;&#x000b5;g/mL, while <italic>M. pneumoniae</italic> (ATCC 15531) and <italic>M. catarrhalis</italic> (ATCC 25238) were the least sensitive strains MIC range = 0.98&#x02013;125&#x02009;&#x000b5;g/mL and MIC range = 3.9 to &#x0003e;125&#x02009;&#x000b5;g/mL, respectively.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>MIC (&#x000b5;g/mL) for hybrids (<bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold>, and <bold>14)</bold> against bronchitis causing-bacteria as determined using XTT assay.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Compound</th><th align="center"><italic toggle="yes">M. pneumoniae</italic> (ATCC 15531)</th><th align="center"><italic toggle="yes">H. influenzae</italic> (ATCC 10211)</th><th align="center"><italic toggle="yes">S. pneumoniae</italic> (ATCC 1659)</th><th align="center"><italic toggle="yes">K. pneumoniae</italic> (ATCC 43816)</th><th align="center"><italic toggle="yes">M. catarrhalis</italic> (ATCC 25238)</th><th align="center"><italic toggle="yes">B. pertussis</italic> (ATCC 9340)</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>5a</bold></td><td align="char" char=".">7.81</td><td align="char" char=".">7.81</td><td align="char" char=".">1.95</td><td align="char" char="."><bold>0.49</bold></td><td align="char" char=".">31.25</td><td align="char" char=".">3.9</td></tr><tr><td align="left"><bold>5b</bold></td><td align="char" char=".">1.95</td><td align="char" char="."><bold>0.98</bold></td><td align="char" char=".">1.95</td><td align="char" char="."><bold>0.49</bold></td><td align="char" char=".">7.81</td><td align="char" char=".">1.95</td></tr><tr><td align="left"><bold>5c</bold></td><td align="char" char=".">31.25</td><td align="char" char=".">7.81</td><td align="char" char=".">3.9</td><td align="char" char=".">1.95</td><td align="char" char=".">NA</td><td align="char" char=".">7.81</td></tr><tr><td align="left"><bold>5d</bold></td><td align="char" char=".">3.9</td><td align="char" char=".">0.98</td><td align="char" char=".">1.95</td><td align="char" char="."><bold>0.49</bold></td><td align="char" char="."><bold>7.81</bold></td><td align="char" char=".">1.95</td></tr><tr><td align="left"><bold>5e</bold></td><td align="char" char=".">7.81</td><td align="char" char=".">7.81</td><td align="char" char=".">1.95</td><td align="char" char=".">0.98</td><td align="char" char=".">15.63</td><td align="char" char=".">7.81</td></tr><tr><td align="left"><bold>5f</bold></td><td align="char" char=".">3.9</td><td align="char" char="."><bold>1.95</bold></td><td align="char" char=".">1.95</td><td align="char" char="."><bold>0.49</bold></td><td align="char" char="."><bold>3.9</bold></td><td align="char" char="."><bold>1.95</bold></td></tr><tr><td align="left"><bold>5g</bold></td><td align="char" char="."><bold>1.95</bold></td><td align="char" char="."><bold>0.98</bold></td><td align="char" char=".">1.95</td><td align="char" char="."><bold>0.24</bold></td><td align="char" char="."><bold>3.9</bold></td><td align="char" char="."><bold>1.95</bold></td></tr><tr><td align="left"><bold>5h</bold></td><td align="char" char="."><bold>1.95</bold></td><td align="char" char="."><bold>0.98</bold></td><td align="char" char=".">1.95</td><td align="char" char="."><bold>0.49</bold></td><td align="char" char="."><bold>3.9</bold></td><td align="char" char="."><bold>1.95</bold></td></tr><tr><td align="left"><bold>5i</bold></td><td align="char" char=".">15.63</td><td align="char" char=".">7.81</td><td align="char" char=".">1.95</td><td align="char" char=".">0.98</td><td align="char" char=".">NA</td><td align="char" char=".">7.81</td></tr><tr><td align="left"><bold>5j</bold></td><td align="char" char=".">3.9</td><td align="char" char=".">3.9</td><td align="char" char=".">1.95</td><td align="char" char="."><bold>0.49</bold></td><td align="char" char="."><bold>7.81</bold></td><td align="char" char="."><bold>3.9</bold></td></tr><tr><td align="left"><bold>5k</bold></td><td align="char" char="."><bold>0.98</bold></td><td align="char" char="."><bold>0.98</bold></td><td align="char" char=".">1.95</td><td align="char" char="."><bold>0.49</bold></td><td align="char" char=".">3.9</td><td align="char" char="."><bold>1.95</bold></td></tr><tr><td align="left"><bold>5l</bold></td><td align="char" char=".">7.81</td><td align="char" char=".">15.63</td><td align="char" char=".">1.95</td><td align="char" char=".">0.98</td><td align="char" char=".">15.63</td><td align="char" char=".">15.63</td></tr><tr><td align="left"><bold>5m</bold></td><td align="char" char=".">62.5</td><td align="char" char=".">7.81</td><td align="char" char=".">7.81</td><td align="char" char=".">1.95</td><td align="char" char=".">NA</td><td align="char" char=".">7.81</td></tr><tr><td align="left"><bold>9a</bold></td><td align="char" char=".">125</td><td align="char" char=".">31.25</td><td align="char" char=".">7.81</td><td align="char" char=".">7.81</td><td align="char" char=".">NA</td><td align="char" char=".">15.63</td></tr><tr><td align="left"><bold>9b</bold></td><td align="char" char=".">125</td><td align="char" char=".">62.5</td><td align="char" char=".">15.63</td><td align="char" char=".">7.81</td><td align="char" char=".">NA</td><td align="char" char=".">31.25</td></tr><tr><td align="left"><bold>9c</bold></td><td align="char" char=".">125</td><td align="char" char=".">15.63</td><td align="char" char=".">15.63</td><td align="char" char=".">3.9</td><td align="char" char=".">NA</td><td align="char" char=".">7.81</td></tr><tr><td align="left"><bold>14</bold></td><td align="char" char=".">3.9</td><td align="char" char="."><bold>1.95</bold></td><td align="char" char=".">1.95</td><td align="char" char="."><bold>0.49</bold></td><td align="char" char=".">15.63</td><td align="char" char="."><bold>1.95</bold></td></tr><tr><td align="left"><bold>Azith.</bold></td><td align="char" char=".">1.95</td><td align="char" char=".">3.9</td><td align="char" char=".">0.98</td><td align="char" char=".">0.49</td><td align="char" char=".">7.81</td><td align="char" char=".">3.9</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><p>NA: not determined.</p></fn><fn id="TF200"><p>Bold values represent the best activity.</p></fn></table-wrap-foot></table-wrap><p>Interestingly, compounds <bold>5g</bold> and <bold>5h</bold> showing best anti-tubercular activity with the minimal bacterial resistance against resistant-TB, revealed a broad-spectrum antibacterial action against most of the tested bronchitis causing-bacteria. They were found to be more potent than the reference drug against <italic>H. influenzae</italic>, <italic>M. catarrhalis</italic>, and <italic>B</italic>. <italic>pertussis</italic> (MIC = 0.24&#x02013;3.9&#x02009;&#x000b5;g/mL, Azithromycin MIC = 3.9&#x02013;7.81&#x02009;&#x000b5;g/mL). Additionally, they were equipotent to Azithromycin against <italic>M. pneumoniae, S. pneumoniae</italic> and <italic>K. pneumoniae</italic> (MIC = 1.95, 0.98, and 0.49&#x02009;&#x000b5;g/mL, respectively).</p><p>Moreover, compound <bold>5k</bold> showed MIC values (0.98-3.9&#x02009;&#x000b5;g/mL) less than that expressed by Azithromycin (MIC = 1.95&#x02013;7.81&#x02009;&#x000b5;g/mL) against four bacterial strains: <italic>M. pneumoniae</italic> (ATCC 15531), <italic>H. influenza</italic>, <italic>M. catarrhalis</italic> (ATCC 25238) and <italic>B. pertussis</italic> (ATCC 9340). Also, compound <bold>5j</bold> was as potent as the reference drug against <italic>H. influenzae, K. pneumoniae</italic> (ATCC 43816), <italic>M. catarrhalis</italic> (ATCC 25238), and <italic>B. pertussis</italic> (ATCC 9340). Furthermore, compounds <bold>5f</bold> and <bold>14</bold> were two-fold more potent (with MIC = 1.95&#x02009;&#x000b5;g/mL) than Azithromycin (MIC = 3.9&#x02009;&#x000b5;g/mL) against <italic>H. influenza</italic> (ATCC 10211) and <italic>B. pertussis</italic> (ATCC 9340) and equipotent to Azithromycin against <italic>K. pneumoniae</italic> (ATCC 43816) with MIC = 0.49&#x02009;&#x000b5;g/mL. Finally, derivatives <bold>5a</bold>, <bold>5b</bold>, and <bold>5d</bold> produced the same MIC values = 0.49&#x02009;&#x000b5;g/mL as that expressed by the standard drug against <italic>K. pneumoniae</italic> (ATCC 43816).</p></sec><sec id="S0002-S2002-S3004" disp-level="3"><label>2.2.4.</label><title>Cytotoxicity against non-tumorigenic lung fibroblast WI-38 cells</title><p>In order to assess the cytotoxic impact of hybrids <bold>5g</bold> and <bold>5h</bold> on normal human cells, an MTT cytotoxicity assay was carried out against non-tumorigenic WI-38 cells. The obtained results ascribed to hybrids <bold>5g</bold> and <bold>5h</bold> non-significant cytotoxic action with IC<sub>50</sub> value = 60.95 and 54.01, respectively (<xref rid="t0003" ref-type="table">Table 3</xref>), thus providing favourable selectivity indices (SI) equal to 15.6 and 13.8, respectively.</p><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p><italic>In vitro</italic> cytotoxic effect for hybrids <bold>5g</bold> and <bold>5h</bold> towards non-tumorigenic WI-38 cells, and their Selectivity index (S.I.).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Compound</th><th align="center">IC<sub>50 <break/></sub>WI-38 cells (&#x000b5;g/mL)</th><th align="center">MIC <break/>Resistant TB (&#x000b5;g/mL)</th><th align="center">Selectivity Index</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>5g</bold></td><td align="center">60.95&#x02009;&#x000b1;&#x02009;3.17</td><td align="center">3.9</td><td align="center">15.6</td></tr><tr><td align="left"><bold>5h</bold></td><td align="center">54.01&#x02009;&#x000b1;&#x02009;2.69</td><td align="center">3.9</td><td align="center">13.8</td></tr></tbody></table></table-wrap></sec></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Molecular docking</title><p>Over the past decade, several druggable targets have been utilised in TB-drug discovery to develop new therapies in order to fight the global epidemic of TB. Most of these enzyme targets have an essential role in energy production, cell wall biosynthesis, and DNA replication, repair, and transcription. Examples of these enzymes are; Alanine racemase (Alr), Maltosyltransferase (GlgE), <italic>N</italic>-Acetylglucosamine-1-phosphate uridyltransferase (GlmU), Pantothenate synthetase (PS), Mtb ATP synthase subunit C (AtpE), Flavin-dependent thymidylate synthase (TS or ThyA), and flavoenzyme Decaprenylphosphoryl-<italic>&#x003b2;</italic>-D-Ribose 2&#x02032;-Epimerase (DprE1)<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref>.</p><p>On account of their superior anti-mycobacterial activity, compounds <bold>5g</bold> and <bold>5h</bold> were selected for further <italic>in silico</italic> investigation to explore their possible molecular target. Two promising drug enzymes in <italic>M. tuberculosis</italic> were suggested as potential targets for the target compounds in this study; the flavoenzyme Decaprenylphosphoryl-<italic>&#x003b2;</italic>-D-Ribose 2&#x02032;-Epimerase (DprE1) and the enoyl-acyl carrier protein reductase (InhA) enzymes. Both enzymes play an essential role in the metabolism of the cell wall and the synthesis of mycolic acid, respectively<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>. The selection of these two enzymes is based on a pilot docking study that explored the plausible binding interactions and energy scores for the prepared compounds with different enzyme targets.</p><p>The crystal structures of the two enzymes were downloaded from the protein data bank PDB ID: 4NCR for DprE1 and 2B35 for InhA. Despite, the importance of docking in providing a predicated binding mode and an account for a ligand strength, it remains a theoretical technique that needs proper validation by comparison with an experimental reference. Therefore, both co-crystallised ligands were re-docked into their corresponding enzymes. The calculated RMSD values between the co-crystallised and docked pose were 0.52 and 0.71 for DprE1 and InhA, orderly which indicates a valid and reliable docking protocol. Compound <bold>5h</bold> has achieved &#x02212;10.1 and &#x02212;7.9&#x02009;kcal/mole energy score for DprE1 and InhA, respectively, whereas, compound <bold>5g</bold> has achieved &#x02212;9.7 and &#x02212;7.3&#x02009;kcal/mole for DprE1 and InhA, respectively. Interestingly, both compounds <bold>5g</bold> and <bold>5h</bold> achieved a higher energy score than the co-crystalized ligand (&#x02212;9.3&#x02009;kcal/mole) in DprE1. These findings suggested that DprE1 may be a plausible target for the herein reported compounds.</p><p>Inspection of the docking poses for the two examined compounds revealed their ability to fit perfectly in the active site of the DprE1 enzyme establishing different types of interactions (<xref ref-type="fig" rid="F0004">Figures 4</xref> and <xref ref-type="fig" rid="F0005">5</xref>). The oxindole ring in both compounds <bold>5g</bold> and <bold>5h</bold> was engaged in two H-bond interactions <italic>via</italic> its carbonyl oxygen (C&#x02009;=&#x02009;O) functionality with His-132 and Tyr-415 amino acids. Furthermore, the NH of the hydrazide linker and the nitrogen atom of the pyridine ring were involved in H-bond interactions with His-132 and Asn-385, respectively. Moreover, the nitrogen atom of the pyridine ring in compound <bold>5h</bold> achieved an extra hydrogen bond interaction with Cys-387 which may explain its higher energy score than <bold>5g</bold>. Worthy of note, the <italic>N</italic>-isobutyl group of compound <bold>5h</bold> established several hydrophobic interactions with non-polar residues lining a hydrophobic pocket, such as Pro-116, Val-121, Ile-131, and Ala-417.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>The 2D diagram and 3D representation for compound <bold>5g</bold> displaying its interactions with the DprE1 binding site.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1868450_F0004_C"/></fig><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>The 2D diagram and 3D representation for compound <bold>5h</bold> displaying its interactions with the DprE1 binding site.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1868450_F0005_C"/></fig><p>The 2&#x02009;D diagrams for interactions of compounds <bold>5g</bold> and <bold>5h</bold> in InhA active site (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1868450">Figure S1</ext-link>), and the 3&#x02009;D illustrations of the superimposition for the docking poses and the co-crystalized ligands in DprE1 and InhA active sites (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1868450">Figure S2</ext-link>), as well as the detailed interactions achieved by compounds <bold>5g</bold> and <bold>5h</bold> within the DprE1 binding site (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1868450">Table S3</ext-link>) were provided in the Supporting Materials.</p></sec><sec sec-type="conclusions" id="S0004" disp-level="1"><label>4.</label><title>Conclusion</title><p>In this work, different sets of isatin-nicotinohydrazide hybrids (<bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold>) and isatin-3-pyridylamine hybrid <bold>14</bold> were designed and synthesised. The anti-mycobacterial activity towards <italic>M. tuberculosis</italic> (ATCC 27294), as well as towards the INH and Streptomycin resistant <italic>M. tuberculosis</italic> (ATCC 35823), were evaluated for the seventeen newly synthesised 2-oxindolin-3-ylidene-nicotinohydrazide derivatives. The obtained results identified compounds <bold>5g</bold> and <bold>5h</bold> as the most potent anti-tubercular agents in this study (MIC = 0.24&#x02009;&#x000b5;g/mL), with minimal mycobacterial resistance (MIC = 3.9&#x02009;&#x000b5;g/mL). Furthermore, all herein reported hybrids were examined for their antibacterial activity against six bronchitis causing-bacteria; <italic>M. pneumoniae</italic>, <italic>H. influenzae</italic>, <italic>K. pneumoniae</italic>, <italic>M. catarrhalis</italic>, <italic>B. pertussis</italic>, and <italic>S. pneumonia</italic>. Most hybrids exerted significant antibacterial activity in comparison to the reference drug Azithromycin against the tested bacterial strains. The most sensitive strain was <italic>K. pneumoniae</italic> with MIC range = 0.49&#x02013;7.81&#x02009;&#x000b5;g/mL. Interestingly, compounds <bold>5g</bold> and <bold>5h</bold> displayed a broad-spectrum antibacterial activity against most of the tested bronchitis causing-bacteria. Moreover, an <italic>in silico</italic> molecular modelling study has proposed DprE1 as a potential enzyme target for herein reported isatin-nicotinohydrazide hybrids. Compounds <bold>5g</bold> and <bold>5h</bold> were able to fit perfectly in the active site of the DprE1 enzyme achieving a higher energy score (&#x02212;9.7 and &#x02212;10.1&#x02009;kcal/mole, respectively) than the co-crystalized ligand (&#x02212;9.3&#x02009;kcal/mole). The oxindole ring was engaged in two H-bond interactions via its carbonyl oxygen (C&#x02009;=&#x02009;O) functionality with His-132 and Tyr-415 amino acids, whereas, the NH of the hydrazide linker and the nitrogen atom of the pyridine ring were involved in H-bond interactions with His-132 and Asn-385, respectively. In addition, the <italic>N</italic>-isobutyl group of compound <bold>5h</bold> established several hydrophobic interactions with non-polar residues lining a hydrophobic pocket.</p></sec><sec id="S0005" disp-level="1"><label>5.</label><title>Experimental</title><sec id="S0005-S2001" disp-level="2"><label>5.1.</label><title>Chemistry</title><sec id="S0005-S2001-S3001" disp-level="3"><label>5.1.1.</label><title>General</title><p>I.R. spectra have been recorded on Schimadzu FT-IR 8400S spectrophotometer. NMR spectra were recorded by Bruker-Avance 400 spectrometer. <sup>13&#x02009;</sup>C NMR spectra were run at 100&#x02009;MHz in deuterated dimethylsulphoxide (DMSO-d<sub>6</sub>). Chemical shifts (<italic>&#x003b4;<sub>H</sub></italic>) are reported relative to the solvent (DMSO-d<sub>6</sub><italic>)</italic>. NMR analyses were carried out at the NMR Unit, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt, whereas IR analyses were carried out at the Faculty of Science, Mansoura University, Mansoura, Egypt. Elemental analyses were carried out at the Regional Centre for Microbiology and Biotechnology, Al-Azhar University, Cairo, Egypt. Compounds <bold>2a</bold>,<bold>b</bold><xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref>, <bold>4a&#x02013;i</bold><xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="CIT0037" ref-type="bibr"><sup>37</sup></xref>, <bold>8</bold><xref rid="CIT0038" ref-type="bibr"><sup>38</sup></xref>, and <bold>11</bold><xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref>, were prepared as described previously.</p></sec><sec id="S0005-S2001-S3002" disp-level="3"><label>5.1.2.</label><title>Synthesis of target compounds 5a&#x02013;m and 9a&#x02013;c</title><p>In a round-bottom flask, the appropriate nicotinohydrazide derivative <bold>2a&#x02013;b</bold> or <bold>8</bold> (2.5&#x02009;mmol) were added to an equivalent amount of <italic>N</italic>-substituted indoline-2,3-dione derivatives <bold>4a&#x02013;i</bold> in 15&#x02009;ml of glacial acetic acid. The previous mixture was heated under reflux with TLC monitoring, after complete consummation of starting materials, the reaction flask was cooled to room temperature. The formed precipitate was collected under vacuum, washed with hexane, cold water and recrystallized from dioxane/methanol mixture to furnish final compounds <bold>5a&#x02013;m</bold> and <bold>9a&#x02013;c</bold>, respectively.</p></sec><sec id="S0005-S2001-S3003" disp-level="3"><label>5.1.3.</label><title>Synthesis of target compound 14</title><p>6-Methoxynicotinoyl azide <bold>12</bold> (0.3&#x02009;g, 1.6&#x02009;mmol) was dissolved in anhydrous toluene (20&#x02009;ml) which then heated under reflux for 1&#x02009;h. To the previous solution, an equivalent amount of 5-bromoisatin was added and the reaction mixture was refluxed for 5&#x02009;h. The produced precipitate was filtrated while hot washed with hexane and recrystallized from acetonitrile to furnish compound <bold>14</bold>.</p><p>Full characterisation details (NMR, IR, and elemental analysis) for the target hybrids (<bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold>, and <bold>14</bold>) have been provided in the Supporting Materials.</p></sec></sec><sec id="S0005-S2002" disp-level="2"><label>5.2.</label><title>Biological evaluation</title><sec id="S0005-S2002-S3001" disp-level="3"><label>5.2.1.</label><title>Anti-tubercular activity</title><p>Microplate Alamar blue assay (MABA)<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref> has been utilised to determine MICs for all herein prepared hybrids (<bold>5a&#x02013;m</bold>, <bold>9a&#x02013;c</bold>, and <bold>14</bold>) against M. tuberculosis ATCC 27294 (Isoniazid-susceptible strain) and <italic>Mycobacterium tuberculosis</italic> ATCC 35823 (Isoniazid and Streptomycin resistant strain). The detailed procedures were presented in the supporting materials.</p></sec><sec id="S0005-S2002-S3002" disp-level="3"><label>5.2.2.</label><title>XTT Susceptibility Assay for the antibacterial activity</title><p>A colorimetric broth microdilution method was utilised to determine the MIC for the tested hybrids following the XTT [2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide]-reduction assay<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>. MICs for the tested hybrids was assessed against bacteria causing bronchitis; Gram-negative bacteria: <italic>H. influenzae ATCC 10211</italic>, <italic>M. pneumoniae ATCC 15531</italic>, <italic>K. pneumoniae ATCC 43816, M. catarrhalis ATCC 25238</italic>, and <italic>Bordetella pertussis ATCC 9340</italic>, as well as <italic>S. pneumoniae ATCC 1659</italic>, representing Gram-positive bacterium, that obtained from the American type culture collection. The detailed experimental procedures have been added in the supporting materials.</p></sec><sec id="S0005-S2002-S3003" disp-level="3"><label>5.2.3.</label><title>Cytotoxicity assay</title><p>The MTT assay<xref rid="CIT0040" ref-type="bibr"><sup>40</sup></xref> was used to assess the cytotoxic impact of hybrids <bold>5g</bold> and <bold>5h</bold> towards the normal human lung WI-38 cells as reported earlier<xref rid="CIT0041" ref-type="bibr"><sup>41</sup></xref>.</p></sec></sec><sec id="S0005-S2003" disp-level="2"><label>5.3.</label><title>Molecular docking</title><p>Aiming to define the molecular target for the best two lead compounds, the crystal structures of both DprE1 and InhA enzymes of TB were downloaded from the Protein data bank ID: 4NCR and 2B35, respectively<xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref><sup>,</sup><xref rid="CIT0043" ref-type="bibr"><sup>43</sup></xref>. Vina Autodock software was implemented in the current work to conduct the docking studies. The program demands both the ligand and the receptor in the pdbqt format, for that, M.G.L tools were used to prepare the two enzymes and the ligands into the right format<xref rid="CIT0044" ref-type="bibr"><sup>44</sup></xref>. Also, the active sites were determined by generating a grid box sized 24&#x02009;&#x000d7;&#x02009;24&#x02009;&#x000d7;&#x02009;24&#x02009;&#x000c5; surrounding the binding domain of each co-crystallised ligand with its corresponding enzyme (centre_x&#x02009;=&#x02009;17.3, centre_y = &#x02212;20 and centre_z&#x02009;=&#x02009;3.4 for 4ncr and centre_x&#x02009;=&#x02009;17, centre_y&#x02009;=&#x02009;12.5 and centre_z&#x02009;=&#x02009;10.5 for 2b35). Docking validity and reliability were ensured by re-docking each co-crystallised ligands with their corresponding enzyme, then calculating the RMSD between the co-crystallised pose and the docked pose. Discovery studio 4.5 visualiser was employed in the analysis of docking results as well as in the evaluation of best candidates based on binding affinity score and interaction with receptor<xref rid="CIT0045" ref-type="bibr"><sup>45</sup></xref>.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM7310"><caption><title>Supplemental Material</title></caption><media xlink:href="IENZ_A_1868450_SM7310.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgement</title><p>This research was funded by the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University through the Fast-track Research Funding Program.</p></ack><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>
<source>Global Tuberculosis Report, WHO</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>WHO</publisher-name>; <year>2019</year>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>
<source>Global Tuberculosis Report, WHO</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>WHO</publisher-name>; <year>2018</year>.</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coninx</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mathieu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Debacker</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>First-line tuberculosis therapy and drug-resistant <italic>Mycobacterium tuberculosis</italic> in prisons</article-title>. <source>Lancet</source>
<year>1999</year>;<volume>353</volume>:<fpage>969</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">10459906</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langbang</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Deka</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kalita</surname><given-names>D.</given-names></name></person-group>
<article-title>A study on bacterial pathogens causing secondary infections in patients suffering from tuberculosis and their pattern of antibiotic sensitivity</article-title>. <source>Int J Curr Microbiol App Sci</source>
<year>2016</year>;<volume>5</volume>:<fpage>197</fpage>&#x02013;<lpage>203</lpage>.</mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pneumonia caused by <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Microb Infect</source>
<year>2020</year>;<volume>22</volume>:<fpage>278</fpage>&#x02013;<lpage>84</lpage>.</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arora</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Krishnaswamy</surname><given-names>UM</given-names></name>, <name name-style="western"><surname>Moideen</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Padmaja</surname><given-names>MS.</given-names></name></person-group>
<article-title>Tubercular and bacterial coinfection: a case series</article-title>. <source>Lung India</source>
<year>2015</year>;<volume>32</volume>:<fpage>172</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">25814806</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Marais</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Mitnick</surname><given-names>CD</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis</article-title>. <source>ERJ Open Res</source>
<year>2017</year>;<volume>3</volume>:<fpage>00026</fpage>.</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunal</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>A.</given-names></name></person-group>
<article-title>The concomitant occurrence of pulmonary tuberculosis with bronchial anthracofibrosis</article-title>. <source>Indian J Tuberc</source>
<year>2017</year>;<volume>64</volume>:<fpage>5</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28166918</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kidwai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jahan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mishra</surname><given-names>NK.</given-names></name></person-group>
<article-title>Isatins: a diversity orientated biological profile</article-title>. <source>Med Chem</source>
<year>2014</year>;<volume>4</volume>:<fpage>451</fpage>&#x02013;<lpage>68</lpage>.</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Fong</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and preliminary antimicrobial analysis of isatin-ferrocene and isatin-ferrocenyl chalcone conjugates</article-title>. <source>ACS Omega</source>
<year>2018</year>;<volume>3</volume>:<fpage>5808</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">30023926</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medvedev</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Buneeva</surname><given-names>O</given-names></name>, <name><surname>Glover</surname><given-names>V</given-names></name><name><surname>.</surname></name></person-group>
<article-title>Biological targets for isatin and its analogues: implications for therapy</article-title>. <source>Biol: Targets Ther</source>
<year>2007</year>;<volume>1</volume>:<fpage>151</fpage>&#x02013;<lpage>62</lpage>.</mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rane</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Karunanidhi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A recent perspective on discovery and development of diverse therapeutic agents inspired from isatin alkaloids</article-title>. <source>Curr Top Med Chem</source>
<year>2016</year>;<volume>16</volume>:<fpage>1262</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">26369813</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandeya</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Smitha</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jyoti</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sridhar</surname><given-names>SK.</given-names></name></person-group>
<article-title>Biological activities of isatin and its derivatives</article-title>. <source>Acta Pharm</source>
<year>2005</year>;<volume>55</volume>:<fpage>27</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">15907222</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tehrani</surname><given-names>KHME</given-names></name>, <name name-style="western"><surname>Hashemi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and antibacterial activity of Schiff bases of 5-substituted isatins</article-title>. <source>Chin Chem Lett</source>
<year>2016</year>;<volume>27</volume>:<fpage>221</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name></person-group>
<article-title>Isatin derivatives and their anti-bacterial activities</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>164</volume>:<fpage>678</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">30654239</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thanh</surname><given-names>ND</given-names></name>, <name name-style="western"><surname>Giang</surname><given-names>NTK</given-names></name>, <name name-style="western"><surname>Quyen</surname><given-names>TH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and evaluation of in&#x000a0;vivo antioxidant, in&#x000a0;vitro antibacterial, MRSA and antifungal activity of novel substituted isatin N-(2,3,4,6-tetra-O-acetyl-&#x003b2;-d-glucopyranosyl)thiosemicarbazones</article-title>. <source>Eur J Med Chem</source>
<year>2016</year>;<volume>123</volume>:<fpage>532</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">27517802</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>W.</given-names></name></person-group>
<article-title>Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>156</volume>:<fpage>580</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">30025351</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name></person-group>
<article-title>Design, synthesis and <italic>in&#x000a0;vitro</italic> anti-mycobacterial activities of homonuclear and heteronuclear bis-isatin derivatives</article-title>. <source>Fitoterapia</source>
<year>2018</year>;<volume>127</volume>:<fpage>383</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">29631015</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akhaja</surname><given-names>TN</given-names></name>, <name name-style="western"><surname>Raval</surname><given-names>JP.</given-names></name></person-group>
<article-title>Design, synthesis, <italic>in&#x000a0;vitro</italic> evaluation of tetrahydropyrimidine&#x02013;isatin hybrids as potential antibacterial, antifungal and anti-tubercular agents</article-title>. <source>Chin Chem Lett</source>
<year>2012</year>;<volume>23</volume>:<fpage>446</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>QB</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>LW.</given-names></name></person-group>
<article-title>Synthesis, crystal structure, and antibacterial activity of oxovanadium (V) complexes derived from N'-[1-(5-fluoro-2-hydroxyphenyl)methylidene]nicotinohydrazide and N'-(5-fluoro-2-hydroxy benzyli dene)-2-hydroxynaphthylhydrazide</article-title>. <source>Russ J Coord Chem</source>
<year>2017</year>;<volume>43</volume>:<fpage>612</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soliman</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Ghabbour</surname><given-names>HA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel 6-phenylnicotinohydrazide derivatives: design, synthesis and biological evaluation as a novel class of antitubercular and antimicrobial agents</article-title>. <source>Biol Pharm Bull</source>
<year>2017</year>;<volume>40</volume>:<fpage>1883</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">29093335</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castelo-Branco</surname><given-names>FS</given-names></name>, <name name-style="western"><surname>de Lima</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Domingos</surname><given-names>JLdO</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>New hydrazides derivatives of isoniazid against <italic>Mycobacterium tuberculosis</italic>: higher potency and lower hepatocytotoxicity</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>146</volume>:<fpage>529</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">29407978</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and anti-mycobacterial activity evaluation of benzofuran-isatin hybrids</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>159</volume>:<fpage>277</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">30296686</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ciprofloxacin-1,2,3-triazole-isatin hybrids tethered via amide: design, synthesis, and in&#x000a0;vitro anti-mycobacterial activity evaluation</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2019</year>;<volume>29</volume>:<fpage>2635</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31358466</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aboul-Fadl</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mohammed</surname><given-names>FAH</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>EAS.</given-names></name></person-group>
<article-title>Synthesis, antitubercular activity and pharmacokinetic studies of some schiff bases derived from 1-alkylisatin and isonicotinic acid hydrazide (inh)</article-title>. <source>Arch Pharm Res</source>
<year>2003</year>;<volume>26</volume>:<fpage>778</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">14609123</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aboul-Fadl</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bin-Jubair</surname><given-names>FAS</given-names></name>, <name name-style="western"><surname>Aboul-Wafa</surname><given-names>O.</given-names></name></person-group>
<article-title>Schiff bases of indoline-2,3-dione (isatin) derivatives and nalidixic acid carbohydrazide, synthesis, antitubercular activity and pharmacophoric model building</article-title>. <source>Eur J Med Chem</source>
<year>2010</year>;<volume>45</volume>:<fpage>4578</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">20696500</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abo-Ashour</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>George</surname><given-names>RF</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel indole-thiazolidinone conjugates: design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>160</volume>:<fpage>49</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">30317025</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abo-Ashour</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>George</surname><given-names>RF</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of 2-aminothiazole-thiazolidinone conjugates as potential antitubercular agents</article-title>. <source>Future Med Chem</source>
<year>2018</year>;<volume>10</volume>:<fpage>1405</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">29788758</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karali</surname><given-names>N</given-names></name>, <name name-style="western"><surname>G&#x000fc;rsoy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kandemirli</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and structure-antituberculosis activity relationship of 1H-indole-2,3-dione derivatives</article-title>. <source>Bioorg Med Chem</source>
<year>2007</year>;<volume>15</volume>:<fpage>5888</fpage>&#x02013;<lpage>904</lpage>.<pub-id pub-id-type="pmid">17561405</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borsari</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ferrari</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Venturelli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Costi</surname><given-names>MP.</given-names></name></person-group>
<article-title>Target-based approaches for the discovery of new antimycobacterial drugs</article-title>. <source>Drug Discov Today</source>
<year>2017</year>;<volume>22</volume>:<fpage>492</fpage>&#x02013;<lpage>502</lpage>.<pub-id pub-id-type="pmid">27663094</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ro&#x0017e;man</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sosi&#x0010d;</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Fernandez</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A new &#x02018;golden age&#x02019; for the antitubercular target InhA</article-title>. <source>Drug Discov Today</source>
<year>2017</year>;<volume>22</volume>:<fpage>492</fpage>&#x02013;<lpage>502</lpage>.<pub-id pub-id-type="pmid">27663094</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>NW</given-names></name>, <name name-style="western"><surname>Saudi</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Abdel-Ghany</surname><given-names>YS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel pyrazine based anti-tubercular agents: design, synthesis, biological evaluation and in silico studies</article-title>. <source>Bioorg Chem</source>
<year>2020</year>;<volume>96</volume>:<fpage>103610</fpage>.<pub-id pub-id-type="pmid">32028062</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tunney</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Ramage</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Field</surname><given-names>TR</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Rapid colorimetric assay for antimicrobial susceptibility testing of <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Antimicrob Agents Chemother</source>
<year>2004</year>;<volume>48</volume>:<fpage>1879</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">15105149</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fathallah</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Raafat</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Issa</surname><given-names>MY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Bio-guided fractionation of prenylated benzaldehyde derivatives as potent antimicrobial and antibiofilm from <italic>Ammi majus</italic> L. fruits-associated <italic>Aspergillus amstelodami</italic></article-title>. <source>Molecules</source>
<year>2019</year>;<volume>24</volume>:<fpage>4118</fpage>&#x02013;<lpage>24</lpage>.</mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finger</surname><given-names>GC</given-names></name>, <name name-style="western"><surname>Starr</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Roe</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Link</surname><given-names>WJ.</given-names></name></person-group>
<article-title>Aromatic fluorine compounds. X. The 2, 3-and 2, 6-difluoropyridines</article-title>. <source>J Org Chem</source>
<year>1962</year>;<volume>27</volume>:<fpage>3965</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Fares</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>HS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and cytotoxic activity of biphenylurea derivatives containing indolin-2-one moieties</article-title>. <source>Molecules</source>
<year>2016</year>;<volume>21</volume>:<fpage>762</fpage>.</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attia</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Afifi</surname><given-names>SA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>New hydrazonoindolin-2-ones: synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres</article-title>. <source>PLoS One</source>
<year>2017</year>;<volume>12</volume>:<fpage>e0181241</fpage>.<pub-id pub-id-type="pmid">28742842</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Al-Rashood</surname><given-names>ST</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and <italic>in&#x000a0;vitro</italic> anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>322</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">30722708</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="patent"><person-group person-group-type="author"><name name-style="western"><surname>Luk</surname><given-names>K-C</given-names></name>, <name name-style="western"><surname>So</surname><given-names>S-S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group> Oxindole derivatives, Patent 7576082, USA; <year>2009</year>.</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosmann</surname><given-names>T.</given-names></name></person-group>
<article-title>Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays</article-title>. <source>J Immunol Methods</source>
<year>1983</year>;<volume>65</volume>:<fpage>55</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">6606682</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Abou-Seri</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>155</volume>:<fpage>782</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">30047410</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makarov</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Lechartier</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Towards a new combination therapy for tuberculosis with next generation benzothiazinones</article-title>. <source>EMBO Mol Med</source>
<year>2014</year>;<volume>6</volume>:<fpage>372</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">24500695</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Truglio</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Boyne</surname><given-names>ME</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>High affinity InhA inhibitors with activity against drug-resistant strains of <italic>Mycobacterium tuberculosis</italic></article-title>. <source>ACS Chem Biol</source>
<year>2006</year>;<volume>1</volume>:<fpage>43</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">17163639</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trott</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Olson</surname><given-names>AJ.</given-names></name></person-group>
<article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title>. <source>J Comput Chem</source>
<year>2010</year>;<volume>31</volume>:<fpage>455</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">19499576</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><element-citation publication-type="web"><ext-link ext-link-type="uri" xlink:href="https://3dsbiovia.com/resource-center/downloads/">https://3dsbiovia.com/resource-center/downloads/</ext-link></element-citation></ref></ref-list></back></article>